What Analysts Think of Eli Lilly Stock Ahead of Earnings
Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...
Jim Cramer Says Eli Lilly and Company (LLY)’s ‘Doing Quite Well’
He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...
Aristotle Atlantic Focus Growth Strategy Increased its Holdings in Eli Lilly and Company (LLY)
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Nasdaq2d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...
Seeking Alpha24d
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...
Business Insider9d
Eli Lilly & Co (LLY) Gets a Buy from Citi
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...
The Motley Fool3d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.
Seeking Alpha5d
Eli Lilly Stock's Correction Brings Opportunity
I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...
Nasdaq11d
Why Eli Lilly Stock Topped the Market Today
Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly ...
Business Insider8d
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...